BACKGROUND The Correa sequence,initiated by Helicobacter pylori(H.pylori),commonly progresses to gastric cancer through the stage of chronic atrophic gastritis(CAG).Although eradication of H.pylori only reduces the ri...BACKGROUND The Correa sequence,initiated by Helicobacter pylori(H.pylori),commonly progresses to gastric cancer through the stage of chronic atrophic gastritis(CAG).Although eradication of H.pylori only reduces the risk of gastric cancer,it does not eliminate the risk for neoplastic progression.Yiwei Xiaoyu granules(YWXY)are a commonly used composite preparation in Chinese clinics.However,the pursuit of excellence in clinical trials and the establishment of standardized animal experiments are still needed to contribute to full understanding and application of traditional Chinese medicine in the treatment of CAG.AIM To demonstrate the effectiveness of YWXY in patients with CAG and spleenstomach deficiency syndrome(DSSS),by alleviating histological scores,improving response rates for pathological lesions,and achieving clinical efficacy in relieving DSSS symptoms.METHODS We designed a double-blind,randomized,controlled trial.The study enrolled seventy-two H.pylori-negative patients(mean age,52.3 years;38 men)who were randomly allocated to either the treatment group or control group in a 1:1 ratio,and treated with 15 g YWXY or 0.36 g Weifuchun(WFC)tablet combined with the respective dummy for 24 wk.The pre-randomization phase resulted in the exclusion of 72 patients:50 participants did not meet the inclusion criteria,12 participants declined to participate,and 10 participants were excluded for various other reasons.Seven visits were conducted during the study,and histopathological examination with target endoscopic biopsy of narrow-band imaging was requested before the first and seventh visits.We also evaluated endoscopic performance scores,total symptom scores,serum pepsinogen and gastrin-17.RESULTS Six patients did not complete the trial procedures.Treatment with YWXY improved the Operative Link on Gastric Intestinal Metaplasia Assessment(OLGIM)stage,compared with WFC(P<0.05).YWXY provided better relief from symptoms of DSSS and better improvement in serum gastric function,compared with WFC(P<0.05).CONCLUSION YWXY compared with WFC significantly reduced the risk of mild or moderate atrophic disease,according to OLGIM stage,significantly relieved symptoms of DSSS,and improved serum gastric function.展开更多
背景胃复春可治疗内镜下剥离术(endoscopic submucosal dissection,ESD)后的胃早癌患者,中性粒细胞-淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)可作为评估此类患者活动度和预后的指标.目前尚未确定不同NLR水平的ESD术后胃早癌...背景胃复春可治疗内镜下剥离术(endoscopic submucosal dissection,ESD)后的胃早癌患者,中性粒细胞-淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)可作为评估此类患者活动度和预后的指标.目前尚未确定不同NLR水平的ESD术后胃早癌患者是否存在与之相关的胃复春疗效差异.目的探讨胃复春对不同NLR水平的胃早癌ESD术后患者的治疗效果.方法选取本院2020-01/2022-12收治的160例胃早癌ESD术后患者,将其分为常规治疗组(n=40)和常规治疗+胃复春治疗组(n=120).将胃复春治疗组再按照NLR水平进行三分位分组,分为高三分位组(NLR≥3.23)40例,低三分位组(NLR≤1.74)40例,中三分位组(NLR:1.74-3.23)40例.比较以上各组治疗前后的主要的消化道症状评分、胃肠激素水平、胃功能指标及血常规指标水平,并计算治疗的总有效率.结果与治疗前比较,治疗后各组患者的胃脘灼热、胃脘胀满、胃脘疼痛和胃纳呆滞评分均降低(P<0.05),其中以低三分位组治疗效果最佳(P<0.05),总有效率最高(P<0.05).常规治疗不能改变患者NLR与血小板-淋巴细胞比值(platelet to lymphocyte ratio,PLR)水平,而常规治疗+胃复春治疗能降低患者的NLR与PLR水平(P<0.05).治疗后,与常规治疗组比较,胃复春治疗组(低、中和高三分位组)的抑胃肽、胃动素、胃泌素、胃蛋白酶原Ⅰ和胃蛋白酶原比值水平均增高(P<0.05)、白细胞、胃蛋白酶原Ⅱ和癌胚抗原均降低(P<0.05),其中以低三分位组最为明显.结论胃复春在不同NLR水平的胃早癌ESD术后患者中均显示出改善消化道症状、胃肠激素、胃功能指标和血常规指标的作用,尤其对于低NLR水平患者而言,治疗效果最为显著.在选择治疗方法时,建议优先考虑低NLR水平的胃早癌ESD术后患者使用胃复春进行治疗.展开更多
基金Supported by the National Natural Science Foundation of China,No.81904175Chongqing Health Planning Commission Project,No.ZY201802063,No.2019ZY013111,No.2022QNXM061+1 种基金Chongqing Performance Incentive Project,No.jxyn2021-1-1Chongqing Technology Innovation and Application Development Special Key Project,No.CSTB2022TIAD-KPX0187.
文摘BACKGROUND The Correa sequence,initiated by Helicobacter pylori(H.pylori),commonly progresses to gastric cancer through the stage of chronic atrophic gastritis(CAG).Although eradication of H.pylori only reduces the risk of gastric cancer,it does not eliminate the risk for neoplastic progression.Yiwei Xiaoyu granules(YWXY)are a commonly used composite preparation in Chinese clinics.However,the pursuit of excellence in clinical trials and the establishment of standardized animal experiments are still needed to contribute to full understanding and application of traditional Chinese medicine in the treatment of CAG.AIM To demonstrate the effectiveness of YWXY in patients with CAG and spleenstomach deficiency syndrome(DSSS),by alleviating histological scores,improving response rates for pathological lesions,and achieving clinical efficacy in relieving DSSS symptoms.METHODS We designed a double-blind,randomized,controlled trial.The study enrolled seventy-two H.pylori-negative patients(mean age,52.3 years;38 men)who were randomly allocated to either the treatment group or control group in a 1:1 ratio,and treated with 15 g YWXY or 0.36 g Weifuchun(WFC)tablet combined with the respective dummy for 24 wk.The pre-randomization phase resulted in the exclusion of 72 patients:50 participants did not meet the inclusion criteria,12 participants declined to participate,and 10 participants were excluded for various other reasons.Seven visits were conducted during the study,and histopathological examination with target endoscopic biopsy of narrow-band imaging was requested before the first and seventh visits.We also evaluated endoscopic performance scores,total symptom scores,serum pepsinogen and gastrin-17.RESULTS Six patients did not complete the trial procedures.Treatment with YWXY improved the Operative Link on Gastric Intestinal Metaplasia Assessment(OLGIM)stage,compared with WFC(P<0.05).YWXY provided better relief from symptoms of DSSS and better improvement in serum gastric function,compared with WFC(P<0.05).CONCLUSION YWXY compared with WFC significantly reduced the risk of mild or moderate atrophic disease,according to OLGIM stage,significantly relieved symptoms of DSSS,and improved serum gastric function.
文摘背景胃复春可治疗内镜下剥离术(endoscopic submucosal dissection,ESD)后的胃早癌患者,中性粒细胞-淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)可作为评估此类患者活动度和预后的指标.目前尚未确定不同NLR水平的ESD术后胃早癌患者是否存在与之相关的胃复春疗效差异.目的探讨胃复春对不同NLR水平的胃早癌ESD术后患者的治疗效果.方法选取本院2020-01/2022-12收治的160例胃早癌ESD术后患者,将其分为常规治疗组(n=40)和常规治疗+胃复春治疗组(n=120).将胃复春治疗组再按照NLR水平进行三分位分组,分为高三分位组(NLR≥3.23)40例,低三分位组(NLR≤1.74)40例,中三分位组(NLR:1.74-3.23)40例.比较以上各组治疗前后的主要的消化道症状评分、胃肠激素水平、胃功能指标及血常规指标水平,并计算治疗的总有效率.结果与治疗前比较,治疗后各组患者的胃脘灼热、胃脘胀满、胃脘疼痛和胃纳呆滞评分均降低(P<0.05),其中以低三分位组治疗效果最佳(P<0.05),总有效率最高(P<0.05).常规治疗不能改变患者NLR与血小板-淋巴细胞比值(platelet to lymphocyte ratio,PLR)水平,而常规治疗+胃复春治疗能降低患者的NLR与PLR水平(P<0.05).治疗后,与常规治疗组比较,胃复春治疗组(低、中和高三分位组)的抑胃肽、胃动素、胃泌素、胃蛋白酶原Ⅰ和胃蛋白酶原比值水平均增高(P<0.05)、白细胞、胃蛋白酶原Ⅱ和癌胚抗原均降低(P<0.05),其中以低三分位组最为明显.结论胃复春在不同NLR水平的胃早癌ESD术后患者中均显示出改善消化道症状、胃肠激素、胃功能指标和血常规指标的作用,尤其对于低NLR水平患者而言,治疗效果最为显著.在选择治疗方法时,建议优先考虑低NLR水平的胃早癌ESD术后患者使用胃复春进行治疗.